Efavirenz-induced urolithiasis

Urological Research

Volumn 34, Issue 4, 2006, Pages 288-289

  Wirth, G J ^a   Teuscher, J ^a   Graf, J D ^a   Iselin, C E ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adverse effects; Chemically induced kidney calculi; Efavirenz; Obstructive pyelonephritis

Indexed keywords

ABACAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE;

ABDOMINAL RADIOGRAPHY; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; ECHOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFRARED SPECTROSCOPY; LABORATORY TEST; LIPODYSTROPHY; MALE; MASS SPECTROMETRY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYELONEPHRITIS; SEPTIC SHOCK; URETER CATHETERIZATION; URINARY TRACT OBSTRUCTION; UROLITHIASIS;

ANTI-HIV AGENTS; HUMANS; MALE; MIDDLE AGED; OXAZINES; PYELONEPHRITIS; URINARY CALCULI;

EID: 33746469416     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-006-0052-6     Document Type: Article

References (3)

1. Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products: European Public Assessment Report (EPAR) on Stocrin/Efavirenz. http://www.emea.eu.int/humandocs/Humans/EPAR/Stocrin/ StocrinM.htm
2. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341:1865
3. Daudon M, Jungers P (2004) Drug-induced renal calculi: epidemiology, prevention and management. Drugs 64:245